Targeting neuroinflammation: a critical opportunity in the evolving landscape of neuropharmacology
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20260448Abstract
Neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia continue to impose an escalating global health burden, yet therapeutic progress has remained disappointingly slow. For decades, neuropharmacology has been dominated by symptomatic approaches-cholinergic modulation, dopaminergic replacement, or glutamatergic stabilization-offering only transient relief without modifying disease trajectory. However, emerging evidence indicates that neuroinflammation is a central, unifying pathological mechanism across neurodegenerative diseases. This paradigm shift has catalyzed a new wave of drug development targeting microglial activation, inflammasomes, complement pathways, and neuroimmune signalling. There is now a compelling need to accelerate translational efforts in this domain, particularly in low-and middle-income countries where the incidence of neurodegenerative disorders is rapidly rising.
Metrics
References
Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388-405. DOI: https://doi.org/10.1016/S1474-4422(15)70016-5
Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell. 2017;169(7):1276-1290.e17. DOI: https://doi.org/10.1016/j.cell.2017.05.018
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368(2):117-27. DOI: https://doi.org/10.1056/NEJMoa1211851
Anderson FL, Biggs KE, Rankin BE, Havrda MC. NLRP3 inflammasome in neurodegenerative disease. Transl Res. 2023;252:21-33. DOI: https://doi.org/10.1016/j.trsl.2022.08.006
Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. J Exp Med. 2020;217:9. DOI: https://doi.org/10.1084/jem.20200785
Dejanovic B, Wu T, Tsai M-C, Graykowski D, Gandham VD, Rose CM, et al. Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer’s disease mouse models. Nat Aging. 2022;2(9):837-50. DOI: https://doi.org/10.1038/s43587-022-00281-1
Lansita JA, Mease KM, Qiu H, Yednock T, Sankaranarayanan S, Kramer S. Nonclinical development of ANX005: A humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases. Int J Toxicol. 2017;36(6):449-62. DOI: https://doi.org/10.1177/1091581817740873
Paolicelli RC, Sierra A, Stevens B, Tremblay M-E, Aguzzi A, Ajami B, et al. Microglia states and nomenclature: A field at its crossroads. Neuron. 2022;110(21):3458-83. DOI: https://doi.org/10.1016/j.neuron.2022.10.020
Gao C, Jiang J, Tan Y, Chen S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther. 2023;8(1):359. DOI: https://doi.org/10.1038/s41392-023-01588-0
Downloads
Published
How to Cite
Issue
Section
